Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS-Reference-Cited by-同舟云学术

Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS

Published:2020-06-25 Issue:2 Volume:1 Page:121-128
ISSN:2688-2663
Container-title:MedComm
language:en
Short-container-title:MedComm

Author:

Ward Antonio B.¹,Keeton Adam B.¹,Chen Xi¹,Mattox Tyler E.¹,Coley Alex B.¹,Maxuitenko Yulia Y.¹,Buchsbaum Donald J.²,Randall Troy D.³,Zhou Gang⁴,Piazza Gary A.¹

Affiliation:

1. Drug Discovery Research Center Department of Pharmacology, Mitchell Cancer Institute University of South Alabama Mobile Alabama

2. Department of Radiation Oncology University of Alabama at Birmingham Birmingham Alabama

3. Department of Medicine, Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham Birmingham Alabama

4. Georgia Cancer Center Augusta University Augusta Georgia

Funder

National Cancer Institute

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mco2.10

Reference78 articles.

1. A Comprehensive Survey of Ras Mutations in Cancer

2. Dragging Ras Back in the Ring

3. RAS oncogenes in human cancer: a review;Bos JL.;Cancer Res,1989

4. Targeting RAS signalling pathways in cancer therapy

5. A new dimension to Ras function: a novel role for nucleotide‐free Ras in Class II phosphatidylinositol 3‐kinase beta (PI3KC2β) regulation;Wong KA;PLoS One,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TG468: a text graph convolutional network for predicting clinical response to immune checkpoint inhibitor therapy;Briefings in Bioinformatics;2024-01-22

2. PTPLAD1 Regulates PHB-Raf Interaction to Orchestrate Epithelial-Mesenchymal and Mitofusion-Fission Transitions in Colorectal Cancer;International Journal of Biological Sciences;2024

3. From structural design to delivery: mRNA therapeutics for cancer immunotherapy;Exploration;2023-11-17

4. Mutation in CDC42 gene set as a response biomarker for immune checkpoint inhibitor therapy;2023-11-11

5. Rubiginosin B selectively inhibits Treg cell differentiation and enhances anti-tumor immune responses by targeting calcineurin-NFAT signaling pathway;Phytomedicine;2023-07